Vol. 21/No. 13 | Oncology Live®

July 09, 2020

During a recent OncLive Peer Exchange, a panel of experts in advanced prostate cancer provided their insights on how best to employ 6 therapies that are enabling men with mCRPC to live longer.

July 08, 2020

Investigators are working on a new generation of therapies that activate CD40, an immune checkpoint that helps promote an antitumor response by boosting T-cell–stimulatory signals.

July 08, 2020

Interim data from a phase 2 study indicate that neoadjuvant hormone therapy may reduce tumor volume in men with high-risk prostate cancer planning to undergo radical prostatectomy.

July 07, 2020

The growing use of genomic profiling technologies will help promote the development of anticancer therapies based on molecular features of a tumor rather than the body site of origin.

July 07, 2020

Lifleucel, a TIL therapy, is being investigated in patients with metastatic melanoma.

July 06, 2020

Toby Campbell, MD, MSCI, discusses the nuances of palliative care in oncology.

July 04, 2020

Shannon N. Westin, MD, MPH, discusses the rationale for administering the maintenance therapy in this setting and the broader potential of regimens combining PARP with other therapies.

July 02, 2020

Suresh S. Ramalingam, MD, discusses the combination of nivolumab and ipilimumab in metastatic non–small cell lung cancer.

July 01, 2020

Precision medicine should be seen as being synergistic―or at a minimum additive―to population medicine.